Amneal PharmaceuticalsvsJohnson & Johnson

AMRX and JNJ stock compared: price, dividend, valuation and results, from SEC filings.

AMRX

Amneal Pharmaceuticals, Inc.

$21.12

Value $7.4B

-0.52%
AMRX's page

Amneal Pharmaceuticals (AMRX) has a market value of $7.4B and Johnson & Johnson (JNJ) $672B. Over the last year, with dividends, AMRX moved +81.4% and JNJ +45.4%. The P/E is 55.2 for AMRX and 41.7 for JNJ. Dividend yield: AMRX none, JNJ 1.89%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    AMRX$7.4B

    JNJ$672B

    JNJ is 91 times AMRX

  • Revenue, 12 months

    AMRX$3.2B

    JNJ$99.3B

    JNJ is 31 times AMRX

  • Net income, 12 months

    AMRX$133M

    JNJ$16.1B

    JNJ is 121 times AMRX

  • Operating margin

    AMRX15.0%

    JNJ–

  • ROIC

    AMRX16.7%

    JNJ12.4%

    4.3 points apart

  • P/E

    AMRX55.2

    JNJ41.7

    AMRX is 1.3 times JNJ

  • Dividend yield

    AMRX0.0%

    JNJ1.9%

    1.9 points apart

  • 5-year return

    AMRX+326.7%

    JNJ+97.0%

    229.7 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

AMRX+326.7%

JNJ+96.9%

20040020222023202420252026
Returns by period
PeriodAMRXWith dividendsJNJWith dividends
1 year since November 14, 2025+81.4%Price +81.4%+45.4%Price +42.2%
3 years since November 17, 2023+366.2%+67.1% a yearPrice +366.2%+102.6%+26.5% a yearPrice +86.1%
5 years since November 16, 2021+326.7%+33.7% a yearPrice +326.7%+97.0%+14.5% a yearPrice +71.3%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

AMRXAmneal PharmaceuticalsJNJJohnson & Johnson

Valuation

AMRXJNJ
Valuation
Price$21.12$278.70
Market value$7.4B$672B
Enterprise value (EV)$10.2B$699B
P/E55.241.7
P/E, 5-year median–21.9
P/B13.98.2
EV/EBIT21.339.4
Free cash flow yield1.2%3.1%

Results and growth

AMRXJNJ
Results and growth
Revenue, 12 months$3.2B$99.3B
Net income, 12 months$133M$16.1B
Free cash flow, 12 months$88M$20.6B
Earnings per share, 12 months$0.42$6.59
Revenue growth, year on year8.1%6.1%
Revenue growth a year, past+8.7%over 5 years+2.7%over 5 years
EPS growth a year, past-18.5%over 5 years+14.9%over 5 years

Margins and returns on capital

AMRXJNJ
Margins and returns on capital
Gross margin40.2%67.6%
Operating margin15.0%–
Net margin4.2%16.2%
ROIC16.7%12.4%
ROE196.8%19.7%

Balance sheet

AMRXJNJ
Balance sheet
Cash$157M$17.2B
Total debt$3.0B$44.7B
Net debt / EBITDA5.31.1
Interest cover–18.0×

Dividends and buybacks

AMRXJNJ
Dividends and buybacks
Dividend yield–1.9%
Dividend per share, 12 months–$5.28
Dividend growth a year, past–+5.3%over 5 years
Buyback yield–0.9%
Shareholder yield–2.8%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: AMRX or JNJ

Didn't find what you were looking for?

Ask us
Which is bigger, Amneal Pharmaceuticals or Johnson & Johnson?

By market value, Johnson & Johnson ($672B) is about 91.3 times Amneal Pharmaceuticals ($7.4B), at today's prices.

How did AMRX and JNJ stock do over the last 5 years?

Since November 16, 2021, AMRX's price moved +326.7% and JNJ's +71.3%. With dividends: AMRX +326.7% (+33.7% a year), JNJ +97.0% (+14.5% a year). Past returns do not predict future ones.

Which pays the higher dividend, AMRX or JNJ?

The dividend yield at today's price is none for Amneal Pharmaceuticals and 1.89% for Johnson & Johnson. Over the last twelve months they paid – and $5.28 per share.

What is the P/E of AMRX and JNJ?

At today's price, the P/E is 55.2 for AMRX and 41.7 for JNJ. It is the share price over the last twelve months' earnings per share.

Which has the higher profit margins, Amneal Pharmaceuticals or Johnson & Johnson?

Over the last twelve months, the net margin was 4.2% for Amneal Pharmaceuticals and 16.2% for Johnson & Johnson, and the operating margin 15.0% and –. Revenue was $3.2B and $99.3B.

Which is the better investment, Amneal Pharmaceuticals or Johnson & Johnson?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.